Listen: Orthocell Is Pioneering Suture-less Repair Of Soft Tissue
In a recent statement, the regenerative medicine company Orthocell is proud to announce their patent for “Suture-less Repair of Soft Tissue” has gone through. This of course refers to the method repairing damaged soft tissue without needing to stitch the wound shut. It’s an exciting time to be in the medical world as Managing…
This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.
Get featured
Want to get featured in MarketScale Healthcare?
Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.
In a recent statement, the regenerative medicine company Orthocell is proud to announce their patent for “Suture-less Repair of Soft Tissue” has gone through. This of course refers to the method repairing damaged soft tissue without needing to stitch the wound shut. It’s an exciting time to be in the medical world as Managing Director of Orthocell, Paul Anderson had this to say, “This is an important addition to our current global IP portfolio. Not only does it further strengthen our IP position in regenerative medicine products and surgical techniques for soft tissue repair, but it also acts to validate CelGro as a collagen medical device platform. The company believes that this innovation has the potential to offer a wider application range in existing markets like bones, tendons, nerves, and even cartilage reconstruction. Looks to me like this is an exciting day for the medical field!
Your experts belong here
Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.
Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.
